Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
veltuzumab
- Development stage
- Phase 2
- Lead developer
- Gilead Sciences
- Modality
- Recombinant Proteins and Enzymes, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Veltuzumab is a humanized IgG1 type I monoclonal antibody that targets the CD20 antigen expressed on B lymphocytes. It was developed as an anti-CD20 therapy with enhanced binding avidity and increased complement-dependent cytotoxicity (CDC) compared to rituximab. Veltuzumab induces cell death in CD20-expressing cells through mechanisms including complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC). It differs from rituximab by only one amino acid in the complementarity-determining region but has a distinct framework that results in lower off-rates and improved CDC activity. The drug was primarily investigated for non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), idiopathic thrombocytopenic purpura (ITP), pemphigus, and rheumatoid arthritis[1][2][3][4][5][6][7].
- Other names
- veltuzumabIMMU-106IMMU106IMMU 106hA20hA-20hA 20humanized anti-CD20 monoclonal antibody
02
Targets
Beyond the preview
Go deeper on veltuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on veltuzumab.